0.00Open0.00Pre Close0 Volume0 Open Interest95.00Strike Price0.00Turnover1187.82%IV-21.74%PremiumNov 29, 2024Expiry Date16.97Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9749Delta0.0077Gamma4.58Leverage Ratio-8.3041Theta-0.0001Rho-4.46Eff Leverage0.0004Vega
DexCom Stock Discussion
Revenue came in at $994.2 million, topping the forecast of $990.71 million and showing growth from last year's $975 million.
The company announced that Teri Lawver, EVP and Chief Commercial Officer, will retire by year-end, with CEO Kevin Sayer temporarily leading the commercial team.
DexCom reaffirmed its 2024 sales outl...
Great products sells itself, ask novo disk and how they sell ozempic
No comment yet